Carlsbad drugmaker Isis Pharmaceuticals said Dec. 17 that Abbott has purchased the remaining piece of subsidiary Ibis Biosciences for $175 million.
Earlier this year, Abbott invested $40 million in Ibis in exchange for 20 percent ownership in the company, which makes a biosensor system used by researchers for identifying infectious agents.
In all, Abbott will pay $215 million, in addition to future payments on the sales of Ibis systems, including instruments and assay kits.
The deal is expected to close in January after it undergoes regulatory approval.
- Advertisement -
, Heather Chambers
